Results 101 to 110 of about 190,265 (268)

Clinical Experience With Eliglustat in Children With Gaucher Disease Type 1

open access: yes
American Journal of Medical Genetics Part A, EarlyView.
Erika R. Vucko   +6 more
wiley   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng   +7 more
wiley   +1 more source

Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Temporal shifts in patient characteristics can influence comparative treatment effects within a certain indication. We investigated patient characteristics and comparative effectiveness and safety for direct oral anticoagulants (DOACs) and warfarin over the time period where DOACs replaced warfarin as preferred stroke prophylaxis in patients with ...
Raoul B. L. J. van den Hemel   +6 more
wiley   +1 more source

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal   +8 more
wiley   +1 more source

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9

open access: yesCytoskeleton, EarlyView.
ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook   +2 more
wiley   +1 more source

Virtual Twin Approach Using Physiologically Based Pharmacokinetic Modeling to Support Precision Dosing of Valproic Acid in Geriatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang   +2 more
wiley   +1 more source

Model for End‐Stage Liver Disease/Pediatric End‐Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation

open access: yesLiver Transplantation, EarlyView., 2022
Abstract Hepatopulmonary syndrome (HPS) is associated with increased waitlist mortality in liver transplantation (LT) candidates. Children with HPS are granted Model for End‐Stage Liver Disease (MELD)/Pediatric End‐Stage Liver Disease (PELD) exception points for waitlist prioritization in the United States based on criterion developed for adults.
Muhammad H. Raza   +8 more
wiley   +1 more source

Risk factors for thrombocytopenia associated with intravenous valproic acid therapy in pediatric patients undergoing neurosurgical operations

open access: yesScientific Reports
Thrombocytopenia is one of the side effects of VPA. This study aimed to evaluate the incidence and risk factors of thrombocytopenia after intravenous VPA treatment in children with neurosurgical operations.
Zhaosong Du   +4 more
doaj   +1 more source

A Practical Guide to Implementing Real‐World Evidence as Primary Basis for Approval and Label Expansion

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
In June 2026, the FDA issued a revised draft guidance describing the circumstances in which one adequate and well‐controlled clinical investigation plus confirmatory evidence may satisfy the statutory substantial evidence standard for establishing efficacy and safety. Confirmatory evidence includes real‐world evidence (RWE).
Tracy J. Mayne   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy